Eight Advisory has been mandated by Idia Capital Investissement and Socadif Capital Investissement to carry out the financial due diligence for the buy-side of Delbert Laboratories in the context of their acquisition. This transaction was carried out with a consortium of investors including Sagard NewGen and MACSF.
Delbert Laboratories specializes in the reintroduction on the market of molecules which, despite their major therapeutic nature, are neglected by pharmaceutical companies.
Delbert Laboratories takes care of all aspects related to the reintroduction of drugs, often with production relocation issues: formulation review, search for a manufacturer in Europe and pricing policy. With a team of 12 employees, the Paris-based SME will achieve a turnover of €15M by 2020.
Eight Advisory carried out the buy-side due diligence on behalf of Idia Capital Investissement and Socadif Capital Investissement. The team was composed of Boris Bignon and Marine Guillou.